Patents by Inventor Tero Satomaa
Tero Satomaa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160215256Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: December 29, 2015Publication date: July 28, 2016Inventors: Johanna Nystedt, Heidi Anderson, Leena Valmu, Jari Natunen, Tero Satomaa
-
Patent number: 9382512Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: January 17, 2012Date of Patent: July 5, 2016Assignee: GLYKOS FINLAND OYInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20160106860Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: ApplicationFiled: May 2, 2014Publication date: April 21, 2016Inventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20160068818Abstract: The invention relates to a method for generating induced pluripotent stem cells, wherein the method comprises: step a) of inducing non-pluripotent cells to produce a mixture comprising induced pluripotent stem cells and non-pluripotent cells; step b) of contacting the mixture comprising induced pluripotent stem cells and non-pluripotent cells obtainable from step a) with a binding agent, wherein the binding agent is capable of binding an epitope consisting of the non-reducing terminal saccharide structure according to formula (Fuc?1-2)aGal?1-3HexNAc?, wherein a=0 or 1 and Hex is either Glc or Gal; and step c) of selecting an induced pluripotent stem cell bound by the binding agent.Type: ApplicationFiled: April 16, 2014Publication date: March 10, 2016Applicant: Glykos Finland OyInventors: Milla MIKKOLA, Timo OTONKOSKI, Heli Mononen, Tero SATOMAA, Juhani SAARINEN
-
Patent number: 9234169Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: July 16, 2009Date of Patent: January 12, 2016Assignee: Glykos FinlandInventors: Johanna Nystedt, Heidi Anderson, Leena Valmu, Jari Natunen, Tero Satomaa
-
Publication number: 20150314007Abstract: The invention relates to novel linker-payload molecule conjugates. The invention also relates to novel cell binder-linker-payload molecule conjugates, in particular antibody conjugates of dolastatin or auristatin derivatives.Type: ApplicationFiled: December 20, 2013Publication date: November 5, 2015Applicant: Glykos Finland OyInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM, Henna PYNNĂ–NEN
-
Publication number: 20150210777Abstract: The invention relates to a pharmaceutical composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn (asparagine) residue and an oligosaccharide structure attached thereto, wherein said oligosaccharide structure has a structure according to formula I, wherein at least 10% of the oligosaccharide structures attached to glycoproteins in the composition consist of oligosaccharide structures according to formula I.Type: ApplicationFiled: December 13, 2012Publication date: July 30, 2015Inventors: Tero Satomaa, Juhani Saarinen, Jari Natunen, Anja Vilkman, Heidi Virtanen, Jukka Hiltunen
-
Publication number: 20150191544Abstract: The invention relates to a composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn (asparagine) residue and an oligosaccharide structure attached thereto, wherein said oligosaccharide structure has a structure according to formula I; and wherein at least 20% of the oligosaccharide structures attached to glycoprotein in the composition consist of oligosaccharide structures according to formula (I).Type: ApplicationFiled: December 13, 2012Publication date: July 9, 2015Inventors: Tero Satomaa, Juhani Saarinen, Jari Natunen, Anja Vilkman, Heidi Virtanen, Jukka Hiltunen
-
Publication number: 20150140576Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.Type: ApplicationFiled: October 24, 2014Publication date: May 21, 2015Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
-
Publication number: 20150072419Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: ApplicationFiled: March 6, 2014Publication date: March 12, 2015Inventors: Tero SATOMAA, Jari NATUNEN, Jarmo LAINE, Annamari HEISKANEN, Maria BLOMQVIST, Anne OLONEN, Juhani SAARINEN, Taina JAATINEN, Ulla IMPOLA, Milla MIKKOLA, Heidi ANDERSON
-
Publication number: 20140248697Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: April 14, 2014Publication date: September 4, 2014Applicant: GLYKOS FINLAND OYInventors: Jarmo LAINE, Taina JAATINEN, Heidi ANDERSON, Johanna NYSTEDT, Sari TIITINEN, Anita LAITINEN, Ulla IMPOLA, Tero Satomaa, Jari NATUNEN, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20140234318Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: GLYKOS FINLAND OYInventors: Jari NATUNEN, Susann TENEBERG, Karl-Anders KARLSSON, Tero SATOMAA, Annamari HEISKANEN
-
Patent number: 8759005Abstract: The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods.Type: GrantFiled: July 11, 2006Date of Patent: June 24, 2014Assignee: Glykos Finland OyInventors: Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen
-
Patent number: 8703488Abstract: The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.Type: GrantFiled: July 13, 2009Date of Patent: April 22, 2014Assignees: Suomen Punainen Risti Veripalvelu, Glykos Finland OyInventors: Ulla Impola, Minna Tiittanen, Milla Mikkola, Jukka Partanen, Jari Natunen, Tero Satomaa, Juhani Saarinen
-
Patent number: 8697061Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.Type: GrantFiled: August 20, 2003Date of Patent: April 15, 2014Assignee: Glykos Finland OyInventors: Jari Natunen, Tero Satomaa
-
Carbohydrate profile compositions from human cells and methods for analysis and modification thereof
Patent number: 8691774Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: GrantFiled: July 11, 2006Date of Patent: April 8, 2014Assignee: Glykos Finland OyInventors: Tero Satomaa, Jari Natunen, Jarmo Laine, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen, Taina Jaatinen, Ulla Impola, Milla Mikkola, Heidi Anderson -
Patent number: 8546353Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: GrantFiled: May 6, 2011Date of Patent: October 1, 2013Assignee: Glykos Finland OyInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Patent number: 8440457Abstract: The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAc?3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.Type: GrantFiled: June 6, 2006Date of Patent: May 14, 2013Assignees: Suomen Punainen Risti, Veripalvelu, Glykos Finland OyInventors: Taina Jaatinen, Heidi Anderson, Jukka Partanen, Jarmo Laine, Tero Satomaa, Jari Natunen, Maria Blomqvist
-
Patent number: 8313912Abstract: The invention concerns a method for diagnosing cancer in a biological sample by determining the presence of a LacdiNAc oligosaccharide sequence. The invention can be used for diagnostic agents, pharmaceutical compositions, cancer vaccines, and antigenic carbohydrate substances. The presence of cancer and malignancies is determined by contacting the biological sample with a reagent that binds to the oligosaccharide sequence. This same method can also be used in the treatment of cancer and malignancies.Type: GrantFiled: August 16, 2002Date of Patent: November 20, 2012Assignee: Glykos Finland OyInventors: Juhani Saarinen, Jari Helin, Tero Satomaa
-
Patent number: 8236487Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.Type: GrantFiled: August 20, 2002Date of Patent: August 7, 2012Assignee: Glykos Finland OyInventors: Jari Natunen, Susann Teneberg, Karl-Anders Karlsson, Tero Satomaa, Annamari Heiskanen